• 1
    Diagnostic and statistical manual of mental disorders, DSM-IV-TR. Washington , DC : American Psychiatric Association, 2000.
  • 2
    Kessler R, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995;52:10481060.
  • 3
    Van Ameringen M. Posttraumatic Stress Disorder in Canada. CNS Neurosci & Ther 2009; in press.
  • 4
    Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006;51(Suppl. 2):57S62S.
  • 5
    Friedman, M. Post-traumatic and acute stress disorders: The latest assessment and treatment strategies, 4th Edition. Kansas City: Compact Clinicals, 2006; 5864.
  • 6
    Ohayon M, Shapiro C. Sleep disturbances and psychiatric disorders associated with posttraumatic stress disorder in the general population. Compr Psychiatry 2000;41:469478.
  • 7
    Krakow B, Schrader R, Tandberg D, Hollifield M, Koss MP, Yau CL, Cheng DT. Nightmare frequency in sexual assault survivors with PTSD. J Anxiety Disord 2002;16:175190.
  • 8
    Van Liempt S, Vermetten E, Geuze E, Westenberg H. Pharmacotherapeutic treatment of nightmares and insomnia in post traumatic stress disorders: An overview of the literature. Ann NY Acad Sci 2006;1071:502507.
  • 9
    Foa EB, Cashman L, Jaycox L, Perry K. The validation of a self-report measure of posttraumatic stress disorders. Psychol Assess 1997;9:445451.
  • 10
    Witkin JM, Tzavara ET, Nomikos GG. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 2005;16:315331.
  • 11
    Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002;418:530534.
  • 12
    Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003;9:7681.
  • 13
    Lynch ME. Preclinical science regarding cannabinoids as analgesics: An overview. Pain Res Manage 2005;10(Suppl. A):7A14A.
  • 14
    Barna I, Zelena D, Arszovski AC, Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: In vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 2004;75:29592970.
  • 15
    Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005;115:31043116.
  • 16
    Chhatwal JP, Davis M, Maguschak KA, Ressler KJ. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2005;30:516524.
  • 17
    Devane WA, Dysarz FA III, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605613.
  • 18
    Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161202.
  • 19
    Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561564.
  • 20
    Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389462.
  • 21
    Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006;105:125.
  • 22
    Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid in chronic noncancer pain. Pain Med 2006;7:2529.
  • 23
    Wissel J, Haydn T, Muller J, Brenneis C, Berger T, Poewe W, Schelosky LD. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain. A double-blind placebo-controlled cross-over trial. J Neurol 2006;20:22182220.
  • 24
    Glass RM, Uhlenhuth EH, Hartel FW, Schuster CR, Fischman MW. Single-dose study of nabilone in anxious volunteers. J Clin Pharmacol 1981;21:383S396S.
  • 25
    Fabre LF, McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 1981;21:377S382S.
  • 26
    Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential. J Psychopharmacol 2005;19:293300.
  • 27
    Bartolucci G. Nabilone and posttraumatic stress disorder in a user of therapeutic marijuana. Four Zero One Pharma, August 2004.
  • 28
    CESAMET™ (nabilone) Product Monograph. Valeant Canada, Ltd. Montreal, Quebec, Canada, 2006.